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This study examines endothelin-induced modulation
of extracellular matrix synthesis and remodeling by
®broblasts, and its potential role in the pathogenesis
of systemic sclerosis (scleroderma). Endothelin-1
promoted ®broblast synthesis of collagen types I and
III, but not ®bronectin, by a mechanism dependent
upon both ETA and ETB receptors. Conversely,
endothelin-1 inhibited both protein expression of
matrix metalloproteinase 1 and zymographic activity
exclusively via ETA receptors. A dual regulatory role
for endothelin-1 in transcriptional regulation was
suggested by the ability of endothelin-1 to enhance
steady-state levels of collagen mRNA and activate
the proa2(I) collagen (Col1a2) promoter, but in con-
trast to reduce matrix metalloproteinase 1 transcript
expression and suppress transcription of a human
matrix metalloproteinase 1 promoter reporter con-
struct in transient transfection assays. Although
endothelin-1 signi®cantly enhanced remodeling of
three-dimensional collagen lattices populated by
normal ®broblasts, this was not observed for lattices
populated by systemic sclerosis ®broblasts.
Promotion of matrix remodeling was dependent
upon ETA receptor expression and was blocked by
speci®c inhibitors of tyrosine kinases or protein
kinase C. Reverse transcriptase polymerase chain
reaction, S1 nuclease, and functional cell surface
binding studies showed that normal and systemic
sclerosis ®broblasts express both ETA and ETB recep-
tors (predominantly ETA), but that ETA receptor
mRNA levels and ETA binding sites on ®broblasts
cultured from systemic sclerosis skin biopsies are
reduced by almost 50%. Endothelin-1 is thus able to
induce a ®brogenic phenotype in normal ®broblasts
that is similar to that of lesional systemic sclerosis
®broblasts. Moreover, reduced responsiveness to
exogenous endothelin-1 in systemic sclerosis suggests
that downstream pathways may have already been
activated in vivo. These data further implicate dysre-
gulated endothelin-receptor pathways in ®broblasts
in the pathogenesis of connective tissue ®brosis. Key
words: collagens/endothelin-1/endothelin receptors/extracel-
lular matrix/®broblasts/interstitial collagenase. J Invest
Dermatol 116:417±425, 2001
E
ndothelin-1 (ET-1) is a 21 amino acid peptide, ®rst
characterized as a potent endothelial cell-derived
vasoconstrictor. It is synthesized as an inactive
precursor polypeptide (preproendothelin) and pro-
cessed to mature active peptides (big endothelin and
endothelin) by zinc metalloproteinases, known as endothelin-
converting enzymes (Shao et al, 1999). Three isoforms of
endothelin are recognized (ET-1, ET-2, ET-3), exhibiting
substantial sequence homology although the extent of functional
overlap is uncertain. In addition to effects on vascular tone (Barton
et al, 1998), endothelins modulate survival, growth, and differ-
entiation of a number of different cell types (Rubanyi and Polokoff,
1994). Elevated circulating levels of ET-1 have been reported in a
wide variety of vascular and in¯ammatory disease states (Levin,
1995), and in the ®brosing connective tissue disease systemic
sclerosis (scleroderma) (Vancheeswaran et al, 1994a). Moreover,
increased endothelin binding has also been demonstrated by
autoradiography in skin and lung biopsies from scleroderma
patients (Vancheeswaran et al, 1994b; Abraham et al, 1997)
suggesting an overall increase in ET receptor expression in disease.
These observations provide evidence that this peptide is involved in
the systemic sclerosis pathogenesis, but do not precisely de®ne its
role in regulating ®broblast properties, nor the pattern of receptor
subtype expression on these cells.
Lesional ®broblasts from biopsies of clinically active systemic
sclerosis skin demonstrate increased matrix biosynthesis (LeRoy,
1974; Jimenez et al, 1986) and reduced degradation (Strehlow and
Korn, 1998). Other fundamental ®broblast properties are also
altered, including proliferative capacity (Ichiki et al, 1995) and
downregulation of collagen gene expression, which normally
occurs in three-dimensional collagen gel cultures (Ivarsson et al,
1993; Shi-Wen et al, 1997). The process by which ®broblasts
acquire this altered phenotype is uncertain, but chronic exposure to
pro®brotic cytokines or growth factors in vivo is postulated. The
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occurrence of vascular damage and endothelial dysfunction
coexisting with, or even preceding, dermal and visceral ®brosis in
systemic sclerosis implicates endothelial cell-derived factors (Car-
valho et al, 1996; Denton et al, 1996) and makes ET-1 a plausible
mediator. We have investigated endothelin-induced modulation of
extracellular matrix turnover and remodeling by normal ®broblasts,
to address the hypothesis that ET-1 is an activator of ®broblasts
with respect to extracellular matrix synthesis, and to delineate the
endothelin receptors and signaling pathways involved.
MATERIALS AND METHODS
Cells and cell culture Fibroblasts were obtained from biopsies of
lesional areas of the skin of patients with early (less than 3 y duration) diffuse
cutaneous systemic sclerosis (n = 8) and from age, sex, and anatomical site
matched healthy volunteers (n = 5). All patients ful®lled the criteria of the
American College of Rheumatology for the classi®cation of systemic
sclerosis (1980). None was receiving immunosuppressive medication or
corticosteroids at the time of biopsy. Fibroblasts were maintained in
Dulbecco's modi®ed Eagle's medium (DMEM) (Gibco, Grand Island, NY)
supplemented with 10% fetal bovine serum (Gibco), 100 U per ml
penicillin, and 100 mg per ml streptomycin, and cultured in a humidi®ed
atmosphere of 5% CO2 in air. Fibroblasts were subcultured at con¯uence
and used between passages 2 and 5.
Measurement of collagen type I and III, and matrix metalloprotein-
ase 1 (MMP-1) production Total collagen type I and III synthesis by
cultured ®broblasts was measured in the absence and presence of ET-1
(concentration range 10±8±10±12 M), by inhibition enzyme-linked
immunosorbent assay (ELISA) (Shi-wen et al, 1997). Culture
supernatants were collected after incubating the cells in the presence of
ascorbate (50 mg per ml) for 48 h. Interstitial collagenase (MMP-1)
concentration in culture supernatants in the absence of ascorbate was
measured using a commercial ELISA kit (Amersham, Buckinghamshire,
U.K.). For inhibition experiments, cells were preincubated in the presence
of endothelin receptor antagonist (100-fold molar excess) for 30 min prior
to initiation of the assay. The speci®c receptor antagonists used were as
follows: ETA receptor antagonist (ETA-RA) PD 156707 (sodium 2-benzo
[1,3]dioxol-5-yl-4-(4-methoxy-phenyl)-4-oxo-3-(3,4,5-trimethoxy-benzyl)-
but-2-enoate), ETB receptor antagonist (ETB-RA) BQ-788 (N-cis-2,6-
dimethylpiperidimocarbonyl-L-gMeLeuD-Nle-ONa), and the mixed
ETA/B receptor antagonist (Bosentan) Ro 47-0203 (4-tert-butyl-N-[6-
(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2,2¢-bipyrimidin-4-yl]-ben-
zenesulfonamine).
Western blot analysis For protein studies ®broblasts were grown to
con¯uence in DMEM with 10% fetal bovine serum, serum starved in
DMEM containing 0.5% bovine serum albumin (BSA) (Sigma, St. Louis,
MO) for 24 h, and then stimulated with ET-1. Culture medium aliquots
were adjusted to 20% (vol/vol) ammonium sulfate and incubated at 4°C
with rotation overnight. Samples were then centrifuged (14,000g for
30 min) at 4°C, and the pellet was resuspended in Laemmli sample buffer
containing b-mercaptoethanol. The cell layer was washed twice with Tris-
buffered saline and cells were directly lyzed by the addition of 1 3 sample
buffer. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) was performed on 12% polyacrylamide gels, and the separated
proteins were transferred onto nitrocellulose membranes at 30 V for
90 min. Membranes were blocked by incubation for 1 h with 5% nonfat
milk in phosphate-buffered saline (PBS) containing 0.2% Tween-20 and
antigens were detected using the following mono-speci®c antibodies: rabbit
antiproa1(I) collagen antibody (directed against the proa1 chain), rabbit
anticollagen type I (directed against collagen type I), and rabbit anticollagen
type III (all from Fibrogen, CA); mouse monoclonal antibody against
human ®bronectin (NovoCastra Laboratories, Newcastle-upon-Tyne,
U.K.); mouse antihuman MMP-1 (Oncogene Research Products,
Boston, MA); goat antihuman actin (Santa Cruz Biotech, CA), all
diluted in PBS. Primary antibody was visualized using a species-speci®c
secondary IgG biotin (Vector Labs, Burlingame, CA) conjugate. Resultant
antigen-antibody complexes were detected by incubation with ABC
reagent (Vector Labs) using the enhanced chemiluminescence substrate kit
(Amersham). Films were analyzed by laser scanning densitometry on an
Ultroscan XL (LKB-Wallac, U.K.), with correction of densitometric units
according to actin signal, as a surrogate for cell number.
Zymography Gelatin and casein zymography was performed using
®broblast culture supernatants from ®broblast cultures grown in the absence
and presence of ET-1 (100 nM) for 48 h. Brie¯y, culture medium (15 ml)
was diluted in SDS loading buffer and applied to precast 10%
polyacrylamide gel Zymogram (Novex, Frankfurt, Germany). Following
electrophoresis at 125 V, 4°C, gels were washed twice with renaturing
buffer at room temperature for 60 min. Zymograms were then transferred
into activity buffer and developed at 37°C for between 4 and 12 h.
Following ®xation and staining with Coomassie Brilliant Blue R-250
(0.25%), the zymograms were destained with 10% (vol/vol) acetic acid.
Transient transfection The following promoter reporter DNA
constructions were used: a Col1a2-luciferase construction containing
±3.5 kb of the human collagen type I alpha 2 gene promoter (from
Francesco Ramirez, Mount Sinai School of Medicine, New York); the
hFNLuc construction, containing a ±1.3 kb fragment of the human
®bronectin promoter (from Noelynn Oliver, FibroGen, San Francisco,
CA); and a ±4.3 kb MMP-1 luciferase plasmid (±4372hMMP1Luc)
containing the human MMP-1 promoter fragment (from Constance
Brinckerhoff, Dartmouth Medical School, New Hampshire). Transient cell
transfection of ®broblasts was carried using FuGene6 transfection reagent
(Roche Molecular Biochemicals) according to the manufacturer's
instructions. Brie¯y, ®broblasts were grown to subcon¯uence, serum
starved for 12 h, and then transfected with the indicated DNA
constructions (0.5±1.0 mg) mixed with FuGene6 and medium in a
standard 50±100 ml volume. Following transfection, cells were washed
and further cultured in medium in the absence and presence of ET-1
(100 nM). After 48 h of incubation the cells were rinsed once with PBS and
lyzed in 200 ml of reporter lysis buffer (Promega, Madison, WI). Reporter
plasmids and pCMV-bGal, pGL3-promoter, and pTK-renilla-Luc used as
internal control for transfection ef®ciency were transfected in a 5:1 ratio.
Luciferase activity was measured by luminometry (Turner Designs,
Sunnyvale, CA) using the Dual-Luciferase Reporter Assay System
(Promega), and b-galactosidase activity was measured according to the
manufacturer's instructions (Tropix, Bedford, MA). Values given are the
means 6 SEM of triplicate assays from three individual experiments.
Preparation of collagen gels and measurement of matrix
remodeling To study collagen gel contraction, ®broblasts were
cultured within three-dimensional collagen lattices (®broblast-populated
collagen lattices, FPCL). These were prepared as previously described
(Ivarsson et al, 1993; Shi-wen et al, 1997). In brief, 24-well tissue culture
plates (Costar) were precoated with sterile 2% BSA in PBS (2 ml per well)
by incubation at 37°C overnight, and were then washed three times with
sterile PBS. For FPCL, neutral collagen solution (containing one part of
0.2 M HEPES, pH 8.0, four parts collagen (Vitrogen-100, 3 mg per ml,
Celltrix, Santa Clara, CA), and ®ve parts of MCDB 104 medium (Sigma,
two times concentrated) was prepared and mixed with ®broblasts that were
resuspended in two times MCDB 104 medium, to bring the ®nal
concentrations to 80,000 cells and 1.2 mg collagen per ml. The collagen-
cell suspension (1 ml) was added to each well and allowed to gel for 1 h.
After polymerization, 1 ml of MCDB medium was added to each well,
causing detachment of the FPCL from the tissue culture plastic. ET-1 was
added at de®ned concentrations and gel contraction was measured up to
48 h. Endothelin receptor antagonists were used as described above, except
that gel contraction was measured at 12 h. To examine the downstream
mediators of ET-1 induced gel remodeling, speci®c inhibitors of signal
transduction pathways were employed. Each inhibitor was added to the
culture medium prior to seeding ®broblasts. Control experiments using
monolayer ®broblast culture and ®broblasts in collagen gel assays
demonstrated that these inhibitors had an effective range of 20±300 mM.
This range was determined by the retention of cell viability of ®broblasts
cultured as monolayers in the presence of increasing concentrations of
inhibitors and the observed optimal gel retraction. Blocking experiments
were performed with inhibitors at a concentration of 200 mM. Thus,
protein kinase C (PKC) activity was inhibited using calphostin C; genistein
and herbimycin A were used to block tyrosine kinases and vanadate to
inhibit phosphatase activity. Fibroblast viability following exposure to
inhibitors was assessed by exclusion of Trypan Blue vital dye (0.4% in
phosphate-buffered saline). Rates of gel contraction were measured by
ocular micrometry, and results are presented as the percentage of initial gel
area or, upon treatment, as the percentage of the retraction rate observed
where the retraction rate in the absence of treatment was taken as 100%.
RNA extraction: northern blots, reverse transcriptase polymerase
chain reaction (RT-PCR), and S1 nuclease analysis Total RNA was
isolated from ®broblasts using the isothiocyanate/caesium chloride method
(Chomczynski and Sacchi, 1987). Levels of speci®c transcripts were
determined by northern blotting, following separation of RNA on 1%
agarose gels containing 2.2 M formaldehyde and capillary transfer to
Hybond N+ membrane (Amersham). Filters were hybridized and probed
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with cDNA fragments speci®c for proa1(I) and proa1(III) collagen,
®bronectin, and MMP-1 mRNAs as previously described (Shi-wen et al,
1997). A glyceraldehyde-3-phosphate dehydrogenase (GAPDH) speci®c
probe was used as an internal standard to allow for differences in amounts of
RNA. Probes were labeled with [a32P]-dCTP to a speci®c activity of 109
dpm per mg, using the Megaprime random priming method (Amersham).
Levels of transcripts were determined from signal intensities after
quantitation performed by Phosphorimager analysis (Molecular
Dynamics, Chesham, Buckinghamshire, U.K.) and adjusted relative to
GAPDH signal intensity. Experiments in the presence of ET-1 and
endothelin receptor antagonist were performed as described above. For
RT-PCR, 5 mg RNA was reverse transcribed using the SUPERSCRIPT
Choice system (Gibco BRL, Paisley, U.K.) and ampli®ed by nested PCR
for ETA and ETB receptor mRNAs as previously described (Pagotto et al,
1995). The PCR consisted of 30 cycles, each cycle consisting of 94°C for
1 min, 45°C for 1 min, and 72°C for 1 min. Speci®c ampli®ed products
(ETA, 299 bp; ETB, 428 bp; and GAPDH, 605 bp) were analyzed on 1.8%
agarose gel and stained with ethidium bromide. GAPDH control primers
(sense 5¢-CTTCACCACCATGGAGAAGG-3¢; antisense 5¢-AGGGCA-
ATGCCAGCCCCAG-3¢; positions cDNA 363±968) were used as
normalization controls for RNA.
Receptor mRNA levels were measured using S1 nuclease analysis as
previously described (Abraham et al, 1997). The PCR fragments for ETA
and ETB receptors were cloned into pGEM-T vector (Promega) and
sequenced, and S1 probes were generated by restriction enzyme and
phosphatase digestion followed by end-labeling with T4 polynucleotide
kinase using [g-32P]-ATP (Abraham et al, 1997). Probes were hybridized to
20±60 mg total RNA for 16 h at 53°C, after which samples were digested
with S1 nuclease (100 U) by incubation at 23°C for 1 h. Following
incubation, digestion was terminated by addition of stop buffer (5 mM Tris-
HCl, 50 mM ethylenediamine tetraacetic acid, 1.0% SDS, 10 mg tRNA,
pH 7.4) and protected fragments were resolved on 8% denaturing
polyacrylamide gel. Transcript levels were determined from signal
intensities by phosphorimager analysis (Molecular Dynamics), and are
presented relative to levels of the control b-actin RNA transcript. Data
summarize three scleroderma and three normal ®broblast strains.
Endothelin A and B receptor binding kinetics Receptor binding
studies were performed on con¯uent ®broblasts cultured in 96-well plates.
Washing ®broblasts in 50 mM Tris-HCl, pH 7.4, buffer three times at room
temperature reduced endogenous peptide levels. Cells were then incubated
for 2 h in binding buffer (PBS containing 5 mM MgCl2, 100 kIU per ml
aprotinin, and 1% BSA) containing [125I]-ET-1, or the ETA selective ligand
([125I]-PD151242), or the ETB selective ligand ([125I]-BQ3020), over the
concentration range 0.3±1000 pM. Non-speci®c binding was established in
the presence of 1 mM unlabeled ET-1. After incubation, cells were rinsed
with buffer at 4°C, harvested by treatment with cell lysis buffer for 10 min
(0.25 M NaOH containing 0.5% SDS), and counted using a Packard
gamma counter. Speci®c binding was determined by subtracting
nonspeci®c from total binding, and receptor density and af®nity [BMAX
(sites per cell) and KD] were calculated using GraphPad InPlot software
(Graph Pad, San Diego, CA).
In order to study ET receptor binding characteristics, con¯uent normal
and systemic sclerosis ®broblasts were incubated (in triplicate) at a ®xed
concentration (approximate KD value, 150 pM) of speci®c ligand, and
binding kinetics were determined as above. Experiments using radiolabeled
ET-1 and receptor selective ligands characterized ®broblast endothelin
receptor binding kinetics. Dissociation constant values (KD) were
determined using saturation binding studies where the radiolabeled ligands
(over a 4-fold log range of concentrations) were incubated with ®broblast
Figure 1. Endothelin-1 modulates matrix
synthesis by ®broblasts. (A) Time course of the
effects of ET-1 on upregulation of proa1(I)
collagen production in normal ®broblasts. Fibro-
blasts were incubated with ET-1 (100 nM) for
between 0 and 72 h and proa1(I) collagen was
determined by Western blot analysis. Densito-
metric units are corrected according to signals for
actin. (B) Collagen (I and III) secretion by normal
(n = 6) ®broblasts is increased by incubation with
ET-1 (10±7 M) for 48 h. Under these culture con-
ditions, ®bronectin production and secretion is
unchanged, whereas MMP-1 secretion is signi®-
cantly reduced. Conditioned medium from ®bro-
blasts was examined using SDS-PAGE followed
by Western blot. These effects could be comple-
tely abolished by coincubation with the mixed
ETA/B receptor antagonist bosentan. Data are
representative of three separate experiments.
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monolayers as described above. Values for the number of endothelin
receptor binding sites per cell are given as means 6 SEM for ®ve individual
cell lines.
Statistical analysis All results are expressed as means 6 SEM unless
otherwise stated. Student's t test was used for statistical analyses. p-values
less than 0.05 were considered statistically signi®cant.
RESULTS
ET-1 enhances synthesis of collagen types I and III and
inhibits the production of interstitial collagenase (MMP-
1) Normal dermal ®broblasts treated with ET-1 showed a dose-
and time-dependent increase in proa1(I) collagen chain production
(Fig 1A). This was apparent at 1 nM and maximal induction was at
100 nM ET-1 (data not shown). Elevated collagen type I
production above basal levels was observed from 8 h post-
treatment and was maximal at 72 h. ET-1 also signi®cantly
enhanced ®broblast production of collagen type III. The
induction of type III collagen was dose dependent (data not
shown), again reaching maximal levels after 48 h of culture
(Fig 1B). Treatment of normal ®broblasts with ET-1 had no
signi®cant in¯uence on the production or secretion of ®bronectin
(Fig 1B). In contrast, there was suppression of MMP-1 secretion,
determined by Western blot analysis, in response to ET-1 (Fig 1B).
Blocking studies showed that the mixed selective ligand bosentan
(ETA and ETB receptor antagonist) blocked ET-1 induced collagen
type I synthesis (p < 0.01). Neither an ETA selective receptor
antagonist (PD156707) nor an ETB receptor antagonist (BQ-788)
alone blocked induction of collagen secretion, however, even at
concentrations that saturate subtype-speci®c binding, suggesting
that signaling via both receptor types was necessary for this effect
(Fig 2A). Similar results were obtained for type III collagen (data
not shown). In contrast to the inductive effects of ET-1 on collagen
type I and III synthesis, incubation with ET-1 resulted in a
signi®cant decrease in MMP-1 expression by normal ®broblasts
(p < 0.01) (Fig 2B). The suppression of interstitial collagenase by
ET-1 was not in¯uenced by the presence of ETB receptor selective
antagonists, but could be prevented by the addition of either the
mixed (ETA and ETB) or ETA receptor antagonist (Fig 2B).
Examination of MMP-1 activity using zymography (data not
shown) also con®rmed that the in¯uence of ET-1 on MMP-1 was
mediated by the ETA receptor.
ET-1 modulates extracellular matrix gene transcription and
expression To determine whether changes in extracellular
matrix protein levels were due to altered gene expression,
collagen a1(I), a1(III), collagenase (MMP-1), and ®bronectin
genes were studied in ®broblasts grown in monolayers in the
presence of ET-1. The expression pro®les of these genes in normal
®broblasts are compared with those of lesional systemic sclerosis
®broblasts in Fig 3(A). The latter exhibit increased steady-state
levels of transcripts of proa1(I), proa1(III) collagen, and
®bronectin, but substantially reduced levels of MMP-1 mRNA
(Fig 3A). Normal ®broblasts treated with ET-1 showed a
signi®cant upregulation of proa1(I) and proa1(III) collagen
mRNA but downregulation of collagenase (MMP-1). Consistent
with the protein data, there was little effect on ®bronectin mRNA
level (Fig 3B). Incubation of normal ®broblasts with ET-1 in the
presence of bosentan blocked the inductive in¯uence of ET-1 on
proa1(I) and proa1(III) collagen mRNA (Fig 3B). Inhibition of
MMP-1 mRNA level by ET-1 could be blocked by an ETA
receptor selective antagonist alone (Fig 3B), but both ETA and ETB
receptor blockade was necessary to prevent collagen I or III mRNA
induction. To explore further the ET-1 mediated changes in
steady-state levels of matrix gene transcripts we undertook a series
of experiments to examine changes in gene transcription. Using
promoter-reporter constructions we observed that ET-1 induced
the transcription of the luciferase reporter gene driven by the
Col1a2 promoter, but conversely exerted a signi®cant suppressive
in¯uence on the human MMP-1 promoter sequence (Fig 4). In
contrast, the ®bronectin promoter was found to be nonresponsive
to ET-1.
ETA receptor activation promotes collagen matrix
contraction by ®broblasts Within the environment of a
three-dimensional collagen lattice (FPCL) ®broblasts interact with
the collagen ®bers and contract the collagen framework into a
compact tissue-like matrix (Grinnell, 1994) (Fig 5A, B). Addition
of ET-1 resulted in a pronounced dose-dependent increase in
FPCL contraction over a 24 h period (Fig 5C), with maximum
contraction elicited by > 10 nM ET-1. Under these conditions
contraction was ®rst apparent at 4 h, and was maximal by about
48 h of culture (Fig 5D). Comparison of FPCL contraction rates
(ET-1 treated or untreated) showed that, whereas the ®nal extent of
contraction was similar, ET-1 enhanced the contraction at earlier
time points, to an extent that was apparent after 4 h and became
signi®cant at 12 h (p = 0.04) (Fig 5D). This time point was later
used to investigate receptor activation and downstream signaling
pathways involved in promotion of collagen lattice contraction.
Using subtype-speci®c antagonists the promotion of lattice
retraction was shown to be mediated via ETA receptors as an
ETA antagonist, or a combined ETA/ETB receptor antagonist, but
not ETB receptor blockade, prevented ET-1 effects although it did
Figure 2. ET-1 induced changes in secretion of collagen depend
upon both ETA and ETB receptor subtypes. (A) Collagen secretion by
normal ®broblasts (n = 6) was increased by incubation with ET-1 (10±7 M)
for 48 h. PD 156707 and BQ 788 (10 mM) alone did not prevent the
increase in collagen type I synthesis by ET-1. Collagen induction can be
effectively abolished by coincubation with the mixed ETA/B receptor
antagonist bosentan (10 mM), however. (B) Incubation of ®broblasts with
ET-1 resulted in a decrease in interstitial collagenase (MMP-1) production.
This suppression could be abolished by coincubation with either the mixed
ETA/B receptor antagonist bosentan or the ETA selective receptor
antagonist PD 156707. Data presented are means (6 SEM) of four
independent experiments. *Signi®cant (*p < 0.05, Student's unpaired t test)
with respect to control values.
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not in¯uence basal contraction (Fig 6A). Comparison of collagen
gel matrix contraction by normal and scleroderma ®broblasts
con®rmed our previous ®ndings that over a 48 h period both
®broblast populations induced contraction of the collagen gel lattice
of around 80%±90% (Shi-wen et al, 1997). When time course and
ET-1 dose-dependent gel contraction experiments were also
performed using scleroderma ®broblasts, however, differences in
the kinetics of gel contraction were revealed. Normal cells were
signi®cantly more responsive than systemic sclerosis ®broblasts
(Fig 6B). The mixed receptor antagonist bosentan reduced ET-1
mediated FPCL contraction, although the response by systemic
sclerosis cells did not reach signi®cance.
Studies using speci®c inhibitors of intracellular signaling path-
ways suggest that gel contraction is dependent upon PKC and
tyrosine kinase activity. Thus ET-1 induced (Fig 7) collagen lattice
contraction was blocked by calphostin C, an inhibitor of PKC
signaling pathways, and by genistein, a broad spectrum kinase
inhibitor, although not by the more selective tyrosine kinase
inhibitor herbimycin A, or by an inhibitor of intracellular
phosphatases (vanadate) (Fig 7). This suggests that the pathways
stimulated by ET-1 that control extracellular matrix contraction
and remodeling involve both PKC signaling and speci®c tyrosine
kinases.
Altered endothelin receptor expression by systemic sclerosis
®broblasts Normal and systemic sclerosis ®broblasts expressed
both ETA and ETB receptor mRNA transcripts (Fig 8A). S1
nuclease analysis demonstrated a signi®cant reduction in expression
of the ETA receptor subtype mRNA in systemic sclerosis ®broblasts
compared with control cells (Fig 8B) but no difference between
ETB receptor mRNA levels. Ligand binding experiments allowed
endothelin receptor KD values to be determined and the number of
Figure 3. ET-1 induces matrix mRNA ex-
pression in control ®broblasts. (A) Total cellu-
lar RNA from normal or scleroderma ®broblast
strains (n = 2) were analyzed by northern hybridi-
zation. Transcripts for proa1(I) collagen,
proa1(III) collagen, ®bronectin, MMP-1, and
GAPDH were localized using radiolabeled cDNA
probes. Lanes 1, 2, normal ®broblasts; lanes 3, 4,
scleroderma ®broblasts. (B) RNA from con¯uent
skin ®broblasts was analyzed by Northern hybridi-
zation as described above. Lanes 1, normal cells
culture alone; lanes 2, normal cells cultured in the
presence of ET-1 (100 nM for 48 h) and, lanes 3,
in the presence of ET-1 plus endothelin receptor
antagonist(s) as indicated; lane 4, representative
transcript expression from scleroderma ®broblasts.
Transcript levels were quantitated by phosphori-
mager analysis in comparison with the control in-
ternal GAPDH mRNA.
Figure 4. ET-1 modulates transcriptional ac-
tivity of matrix gene promoters. Fibroblasts
were transiently transfected with the DNA repor-
ter constructs containing the Col1a2, ®bronectin,
and MMP-1 human promoter sequences inserted
upstream of a luciferase reporter gene. Results
shown are for three individual experiments and
the values given are expressed as mean 6 SEM
(*signi®cant at p < 0.05).
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binding sites per cell calculated for normal ®broblasts. Dissociation
constant values (Kd) as determined using saturation binding studies
with radiolabeled ligands as described in Materials and Methods were
found to be 149 6 23 pM and 168 6 38 pM for the ETA and ETB
receptors, respectively. In order to compare the levels of endothelin
receptors, normal and systemic sclerosis ®broblast cell lines were
incubated in 150 pM radioligand (the average of the KD values
obtained) for subsequent experiments in the absence or presence of
unlabeled ET-1. Quantitative measurement of the endothelin
receptor levels revealed that both cell types expressed similar
functional levels of ETB receptors (602 6 156 and 645 6 232
binding sites per cell for normal and systemic sclerosis ®broblasts,
respectively). In contrast the number of ETA binding sites on
systemic sclerosis ®broblasts were shown to be dramatically reduced
to almost half the number found on normal cells (4145 6 126 and
2299 6 68.9 binding sites per cell for normal and systemic sclerosis
®broblasts, respectively; p < 0.05). Nonetheless, ETA receptors
were expressed at a level at least 10±20-fold greater than the ETB
subtype.
DISCUSSION
Previous experimental studies suggest that ET-1 stimulates
®broblast collagen synthesis (Kahaleh, 1991; Guarda et al, 1993)
and promotes collagen gel matrix contraction (Guidry and Hook,
1991), an in vitro model for extracellular matrix remodeling. More
recent data from animal experiments con®rm the ®brogenic effect
of ET-1 in vivo. Thus, ET-1 overexpression under the control of an
Figure 5. ET-1 stimulates collagen matrix remodeling by ®bro-
blasts. (A) Morphology of ®broblasts in relaxed three-dimensional
collagen gel pre (left panel) and post (right panel) gel contraction. (B)
Appearance of relaxed three-dimensional collagen gel pre (left panel) and
post (right panel) gel contraction. (C) The effect of different concentrations
of ET-1 on the contraction of collagen gels containing normal ®broblasts
(n = 4). Contraction of gel lattice was assessed by measurement of the
maximum gel diameter. The results are presented as the retraction rate
de®ned as the percentage of contraction observed taking the retraction in
the absence of endothelin as 100%. (D) The in¯uence of ET-1 (100 nM) on
gel contraction by normal ®broblasts. Collagen-cell suspensions were
polymerized in the absence and presence of ET-1 and the rates of
subsequent gel contraction were measured over 48 h.
Figure 6. ET-1 induced gel remodeling is blocked by ETA subtype
speci®c receptor antagonists. (A) The promotion of FPCL contraction
induced by ET-1 is blocked by a speci®c ETA receptor antagonist or by
bosentan (ETA/ETB antagonist) but not by an ETB speci®c antagonist at
concentrations that saturate ET-1 binding via these receptors. (B) At 12 h
post gel polymerization, the extent of three-dimensional gel contraction by
normal and systemic sclerosis ®broblasts was measured in the absence and
presence of ET-1 and in the presence of ET-1 following pretreatment with
the mixed receptor antagonist (bosentan) as indicated. Solid bars, normal
®broblasts; hatched bars, systemic sclerosis ®broblasts.
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endogenous promoter induces interstitial ®brosis of internal organs,
which develops despite only slight increases in plasma and tissue
ET-1 levels (Hocher et al, 1997). Moreover, experimentally
induced models of both hepatic and pulmonary ®brosis are
characterized by elevated ET-1 expression at early stages of the
disease (between days 3 and 7 postinjury), prior to an increase in
collagen deposition (Mutsaers et al, 1998; Rocky et al, 1998). In
addition, liposome-mediated ET-1 gene transfer into rat lungs
results in an obliterative ®brotic disease characterized by appearance
of hyperplastic connective tissue plaques (Takeda et al, 1997).
Our data show that exogenous ET-1 induces types I and III
collagen synthesis, in a dose- and time-dependent manner. In
contrast to its effect on collagen biosynthesis, ET-1 was found to
decrease the level of interstitial collagenase (MMP-1) produced by
®broblasts. As extracellular degradation of native type I collagen
requires initial cleavage by MMP-1, the in¯uence of ET-1 on
interstitial collagenase expression could have substantial effects on
matrix turnover. Interestingly, this inhibition appears to be
dependent only upon ETA receptor activation, in contrast to the
effect on collagen biosynthesis, which could only be prevented by
blocking both ETA and ETB receptor subtypes. Transient
transfection assays using promoter reporter constructions suggested
that the in¯uence of ET-1 on the level of collagen type I, and
MMP-1, was primarily at the transcriptional level. The ability of
ET-1 to activate the Col1a2 promoter yet suppress transcription
from the human MMP-1 suggests a speci®city of ET-1 action that
may be dependent on distinct signaling pathways evoked through
binding to the speci®c receptors. Although we were able to
demonstrate increased ®bronectin production by systemic sclerosis
®broblasts, ET-1 induced no change in ®bronectin expression in
normal cells. This contrasts with the report by Marini et al (1996),
showing an induction of ®bronectin synthesis in bronchial
epithelial cells following ET-1 stimulation, mediated via an ETA
receptor type. The discrepancy may re¯ect different endothelin
receptor expression pro®les, or that distinct responses to ET-1 are
evoked in different cell types via the same receptors.
FPCL represent a more physiologic environment than
standard monolayer culture, and interactions between ®broblasts
and the extracellular collagen modulate properties of ®broblasts
within these lattices. For example, when cultured in FPCL,
®broblasts show altered collagen and interstitial collagenase
expression, and initiate gel lattice contraction (Guidry and
Hook, 1991). In many respects these processes are thought to
be analogous to those that take place in vivo during wound
healing and tissue regeneration (Langholz et al, 1995). Contrac-
tion of gels is dependent upon engagement of collagen-binding
integrins (Grinnell, 1994), and involves re-organization of the
cytoskeleton and redistribution of these cell surface receptors.
ET-1 accelerated the rate of gel contraction in a dose-
dependent manner. Studies performed in the presence of
speci®c endothelin receptor antagonists con®rmed that this
promotion was via activation of ETA receptors. Although ET-1
signaling has previously been shown to involve G-protein
Figure 7. Inhibitors of intracellular signaling pathways block ET-1
induced gel remodeling. The extent of ET-1 induced contraction
(100 nM) in the presence of each inhibitor was compared for a 12 h time
point from lattice seeding as described in Methods. Calphostin C and
genistein blocked the promotion of ®broblast-mediated gel contraction by
ET-1.
Figure 8. ETA receptor mRNA expression and binding sites are
reduced in systemic sclerosis ®broblasts. (A) Agarose gel showing
products of PCR ampli®cation of ETA (299 bp), ETB (428 bp), and
GAPDH (605 bp) cDNA from reverse transcribed mRNA derived form
three separate ®broblast cultures. Lanes 1±3, normal ®broblast strains; lanes
4±6, systemic sclerosis ®broblast strains. (B) S1 analysis was used for
quantitative examination of endothelin receptor subtype expression. S1
probes were hybridized to total ®broblast RNA, and following digestion
the protected fragments corresponding to ETA and ETB receptors and actin
transcripts were separated on 8% denaturing polyacrylamide gels and
visualized by autoradiography. Lane 1, ssDNA standards OX174 HaeIII
digest; lanes 2, 3, normal ®broblasts; lanes 4, 5, scleroderma ®broblasts; lanes
2, 4, ETB probe; lanes 3, 5, ETA probe. (C) ETA receptor mRNA
expression in scleroderma ®broblasts was determined by phosphorimager
and normalized to b-actin.
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linked activation of phospholipase C, the role of PKC in ET-1
induced gel contraction suggested by our data is consistent with
previous reports that basal contraction is PKC dependent
(Langholz et al, 1995). From these studies it appears that
®broblast±collagen interaction via cell surface integrin receptors
leads to activation of PKC, either by direct effects on integrin
expression (Racine-Samson et al, 1997) or by convergence of
downstream signaling pathways. Future experiments should
elucidate this interplay between independently triggered signal-
ing events, and whether these pathways are perturbed in ®brotic
cells.
We have demonstrated that both ETA and ETB receptor
subtypes are functionally expressed and their mRNA transcripts
are present in human ®broblasts. Downregulation of ETA
receptor expression on scleroderma ®broblasts appears to
underlie reduced responsiveness to ET-1 by these cells. This
is consistent with earlier studies showing that exogenous ET-1
provokes a smaller increase in DNA synthesis in scleroderma
than in normal ®broblasts (Kikuchi et al, 1995). Although these
authors observed reduced ETA receptor protein on scleroderma
®broblasts, using Western blot analysis, our data considerably
extend their studies. We have demonstrated expression of
functional ETA and ETB receptors on ®broblasts in tissue
culture by ligand binding assays, although there is around a 20-
fold excess of ETA receptors. These expression data are
con®rmed by analysis of mRNA levels for receptor transcripts,
and detection of ETB receptor transcript contrasts with previous
reports (Kikuchi et al, 1995). Although total ETB expression
does not appear to be different between control and
scleroderma ®broblasts, the relative ETA:ETB ratio will be
perturbed by virtue of the lower ETA levels. Thus, some of the
differences in effects mediated via both receptor subtypes may
arise through this relative difference rather than the absolute
reduction in ETA expression. Our con®rmation of reduced ETA
receptor expression on scleroderma ®broblasts is noteworthy in
view of previous data derived directly from tissue sections that
demonstrated increased ET-1 binding sites in lesional skin or
lung biopsies. This suggests that cells other than ®broblasts, such
as vascular or in¯ammatory species, may be responsible for
increased ligand binding. The basis for reduced ETA receptor
expression on scleroderma ®broblasts is not known, but
potential mechanisms include cell selection resulting in the
expansion of ®broblast populations with reduced ETA receptor
expression; ligand-induced downregulation of receptor expres-
sion as a consequence of elevated ET-1 in vivo; or a reduction
in receptor expression provoked by the presence of elevated
levels of cytokines and growth factors within a ®brotic
environment (Smith et al, 1998).
In conclusion, our study demonstrates that ET-1 stimulates
®broblast collagen (types I and III) production, downregulates
MMP-1, and promotes contraction of FPCL. From our studies
on mRNA expression and promoter reporter constructs it
appears that ET-1 can act to both enhance and suppress
transcription. In the context of ®brosis, this dichotomy may
have a signi®cant impact, on the one hand promoting matrix
production and on the other inhibiting matrix turnover, the net
result being enhanced matrix deposition and accumulation.
Modulation of MMP-1 and collagen gel remodeling were
mediated exclusively via ETA receptors whereas promotion of
collagen gene expression appears to require both receptor
subtypes. In view of the abnormal endothelin receptor pro®les
in systemic ®broblasts, these ®ndings suggest that ET-1 signaling
is altered in scleroderma and that healthy ®broblasts treated with
ET-1 develop a ®brogenic phenotype in vitro. Overall, our data
support the hypothesis that ET-1, possibly derived from
activated or damaged endothelial cells, may be important not
only in the control of vascular tone and abnormal blood vessel
function but also as an activator of ®broblasts in this systemic
sclerosis, and perhaps a potential target for therapeutic
modulation.
The authors would like to thank Dr. M Clozel, Hoffman LaRoche, Switzerland,
for Ro 47-0203 (bosentan). CPD is a Wellcome Trust Advanced Fellow and
MRD is supported by the British Heart Foundation. This work was supported by
the Arthritis Research Campaign (U.K.), Raynaud's and Scleroderma Association
Trust, The Frances and Augustus Newman Foundation, The Nightingale
Charitable Trust, and The Sir Jules Thorn Charitable Trust.
REFERENCES
Abraham DJ, Vancheeswaran R, Dashwood MR, Pantelides P, Shi-wen X, du Bois
RM, Black CM: Increased levels of endothelin-1 and differential endothelin
type A and B receptor expression in scleroderma-associated ®brotic lung
disease. Am J Pathol 151:831±841, 1997
Anonymous: Subcommittee for scleroderma criteria of the American Rheumatism
Association Diagnostic and Therapeutic Criteria Committee: Preliminary
criteria for the classi®cation of systemic sclerosis (scleroderma). Arthritis Rheum
23:581±590, 1998
Barton M, Haudenschild CC, D'Uscio LV, Shaw S, Munter K, Luscher TF:
Endothelin ETA receptor blockade restores NO-mediated endothelial function
and inhibits atherosclerosis in apolipoprotein E-de®cent mice. Proc Natl Acad
Sci USA 95:14367±14372, 1998
Carvalho D, Savage CO, Black CM, Pearson JD: IgG antiendothelial cell
autoantibodies from scleroderma patients induce leukocyte adhesion to
human vascular endothelial cells in vitro. Induction of adhesion molecule
expression and involvement of endothelium-derived cytokines. J Clin Invest
97:111±119, 1996
Chomczynski P, Sacchi N: Single step method of RNA isolation by acid-
guanidinium-phenol-chloroform extraction. Anal Biochem 162:156±159, 1987
Denton CP, Shiwen X, Welsh KI, Pearson JD, Black CM: Scleroderma ®broblast
phenotype is modulated by endothelial cell co-culture. J Rheumatol
23:633±638, 1996
Grinnell F: Fibroblasts, myo®broblasts, and wound contraction. J Cell Biol
124:401±404, 1994
Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT: Effects of endothelins on
collagen turnover in cardiac ®broblasts. Cardiovasc Res 27:2130±2134, 1993
Guidry C, Hook M: Endothelins produced by endothelial cells promote collagen gel
contraction by ®broblasts. J Cell Biol 115:873±880, 1991
Hocher B, Thone-Reineke C, Rohmeiss P, et al: Endothelin-1 transgenic mice
develop glomerulosclerosis, interstitial ®brosis, and renal cysts but not
hypertension. J Clin Invest 99:1380±1389, 1997
Ichiki Y, Smith E, LeRoy EC, Trojanowska M: Different effects of basic ®broblast
growth factor and transforming growth factor-beta on the two platelet-derived
growth factor receptors' expression in scleroderma and healthy human dermal
®broblasts. J Invest Dermatol 104:124±127, 1995
Ivarsson M, McWhirter A, Black CM, Rubin K: Impaired regulation of collagen
pro-a1 (I) mRNA and change in pattern of collagen-binding integrins on
scleroderma ®broblasts. J Invest Dermatol 101:216±221, 1993
Jimenez S, Feldmenn G, Bashey R, Bienkowski R: Co-ordinate increase in the
expression of type II and type III collagen genes in progressive systemic sclerosis
®broblasts. Biochem J 237:837±843, 1986
Kahaleh MB: Endothelin, an endothelial-dependant vasoconstrictor in scleroderma.
Arthritis Rheum 34:978±983, 1991
Kikuchi K, Kadono T, Sato S, Tamaki K, Takehara K: Impaired growth response to
endothelin-1 in scleroderma ®broblasts. Bioche Biophys Res Commun
207:829±838, 1995
Langholz O, Rockel D, Mauch C, Kozlowska E, Bank I, Krieg T, Eckes B: Collagen
and collagenase gene expression in three-dimensional collagen lattices are
differentially regulated by a1b1 and a2b1 integrins. J Cell Biol 131:1903±1915,
1995
LeRoy EC: Increased collagen synthesis by scleroderma skin ®broblasts in vitro: a
possible defect in the regulation or activation of the scleroderma ®broblast. J
Clin Invest 54:880±889, 1974
Levin ER: Endothelins. N Engl J Med 333:356±363, 1995
Marini M, Carpi S, Bellini A, Patalano F, Mattoli S: Endothelin-1 induces increased
®bronectin expression in human bronchial epithelial cells. Biochem Biophys Res
Commun 220:896±899, 1996
Mutsaers SE, Marshall RP, Goldsack NR, Laurent GJ, McAnulty RJ: Effect of
endothelin receptor antagonists (BQ-485, Ro47±0203) on collagen deposition
during the development of bleomycin-induced pulmonary ®brosis in rats. Pulm
Pharmacol Ther 11:221±225, 1998
Pagotto U, Arzberger T, Hopfner U, et al: Expression and localization of endothelin-
1 and endothelin receptors in human meningiomas. Evidence for a role in
tumoral growth. J Clin Invest 96:2017±2025, 1995
Racine-Samson L, Rockey DC, Bissell DM: The role of alpha1beta1 integrin in
wound contraction. A quantitative analysis of liver myo®broblasts in vivo and in
primary culture. J Biol Chem 272:30911±30917, 1997
Rocky DC, Fouassier L, Chung JJ, Carayon A, Vallee P, Ray C, Housset C: Cellular
localization of endothelin-1 and increased production in liver injury in the rat:
potential for autocrine and paracrine effects on stellate cells. Hepatology
27:472±480, 1998
Rubanyi GM, Polokoff MA: Endothelins. Molecular biology, biochemistry,
pharmacology, physiology and pathophysiology. Pharmacol Rev 46:325±415,
1994
Shao R, Yan W, Rockay DC: Regulation of endothelin-1 synthesis by endothelin-
424 SHI±WEN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
converting enzyme-1 during wound healing. J Biol Chem 274:3228±3234,
1999
Shi-Wen X, Denton CP, McWhirter A, Bou-Gharios G, Abraham DJ, du Bois RM,
Black CM: Scleroderma lung ®broblasts exhibit elevated and dysregulated
collagen type I biosynthesis. Arthritis Rheum 40:1237±1244, 1997
Smith PG, Teichert-Kuliszewska K, Monge JC, Stewart DJ: Regulation of
endothelin-B receptor mRNA expression in human endothelial cells by
cytokines and growth factors. J Cardivasc Pharmacol 31:158±160, 1998
Strehlow D, Korn JH: Biology of the scleroderma ®broblast. Current Opin Rheumatol
10:572±578, 1998
Takeda S, Sawa Y, Minami M, et al: Experimental bronchiolitis obliterans induced by
in vivo HVJ-liposome-mediated endothelin-1 gene transfer. Ann Thorac Surg
63:1562±1567, 1997
Vancheeswaran R, Azam A, Black CM, Dashwood MR: Localisation of
endothelin-1 and its binding sites in scleroderma skin. J Rheumatol
21:1268±1276, 1994a
Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Black CM:
Circulating endothelin-1 levels in systemic sclerosis subsets - a marker of
®brosis or vascular dysfunction? J Rheumatol 21:1838±1844, 1994b
VOL. 116, NO. 3 MARCH 2001 ENDOTHELIN-1 PROMOTES TISSUE REMODELING AND FIBROSIS 425
